Sugi Predict

Sugi Predict / Targets / CDK20

CDK20

Cyclin-dependent kinase 20 · Q8IZL9 · CDK20 on Sugi Atlas →

223 patent compounds predicted against CDK20, 182 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL29421607 SCHEMBL29421607 1.00 1/20
SCHEMBL30405852 SCHEMBL30405852 1.00 1/20
SCHEMBL29648491 SCHEMBL29648491 0.73 1/20
SCHEMBL29975793 SCHEMBL29975793 0.73 1/20
SCHEMBL30094663 SCHEMBL30094663 0.73 1/20
SCHEMBL30273058 SCHEMBL30273058 0.73 1/20
SCHEMBL30319807 SCHEMBL30319807 0.73 1/20
SCHEMBL30597674 SCHEMBL30597674 0.73 1/20
SCHEMBL30597679 SCHEMBL30597679 0.73 1/20
SCHEMBL9963854 SCHEMBL9963854 0.72 1/20
SCHEMBL30380971 SCHEMBL30380971 0.70 1/20
SCHEMBL23064865 SCHEMBL23064865 0.70 1/20
SCHEMBL29353719 SCHEMBL29353719 0.70 1/20
SCHEMBL30319805 SCHEMBL30319805 0.68 1/20
SCHEMBL29961097 SCHEMBL29961097 0.68 1/20
SCHEMBL30597663 SCHEMBL30597663 0.68 1/20
SCHEMBL30319763 SCHEMBL30319763 0.67 1/20
SCHEMBL30319777 SCHEMBL30319777 0.67 1/20
SCHEMBL30319862 SCHEMBL30319862 0.67 1/20
SCHEMBL15113154 SCHEMBL15113154 0.65 1/20

Clinical trials — most relevant to CDK20 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer PHASE4NOT_YET_RECRUITING
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Study of AVZO-021 in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer PHASE2COMPLETED
Palbociclib With Everolimus + Exemestane In BC PHASE1/PHASE2COMPLETED
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy PHASE2COMPLETED
Avelumab, Palbociclib and Axitinib in Advanced RCC PHASE2WITHDRAWN
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors PHASE1COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma PHASE1WITHDRAWN
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN
The SONImage Study nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CDK20 binder may also engage these)

ProteinNameSimilarity
Q9JHU3 — 1.000 Q9JHU3 →
Q4KM34 — 1.000 Q4KM34 →
Q5R7I7 — 1.000 Q5R7I7 →
A8WIP6 — 0.994 A8WIP6 →
P51952 — 0.992 P51952 →
Q03147 — 0.990 Q03147 →
Q38774 — 0.990 Q38774 →
P20911 — 0.990 P20911 →
CDK7 Cyclin-dependent kinase 7 0.990 landscape →
P79432 — 0.990 P79432 →
Q32KY4 — 0.990 Q32KY4 →
Q9C9M7 — 0.989 Q9C9M7 →
Q12126 — 0.989 Q12126 →
P30285 — 0.989 P30285 →
CDK6 Cyclin-dependent kinase 6 0.988 landscape →
P35426 — 0.988 P35426 →
Q0J4I1 — 0.987 Q0J4I1 →
G5EFV5 — 0.987 G5EFV5 →
Q8L4P8 — 0.987 Q8L4P8 →
P54666 — 0.987 P54666 →
P51953 — 0.987 P51953 →
P25859 — 0.986 P25859 →
Q38775 — 0.986 Q38775 →
Q91727 — 0.986 Q91727 →
P54665 — 0.986 P54665 →
CDK4 Cyclin-dependent kinase 4 0.986 landscape →
Q8LF80 — 0.985 Q8LF80 →
P54119 — 0.985 P54119 →
P17157 — 0.985 P17157 →
Q9C9U2 — 0.985 Q9C9U2 →